Abstract
Nitric oxide is a pleiotropic ancestral molecule, which elicits beneficial effect in many physiological settings but is also tenaciously expressed in numerous pathological conditions, particularly breast tumors. Nitric oxide is particularly harmful in adipogenic milieu of the breast, where it initiates and promotes tumorigenesis. Epidemiological studies have associated populations at a greater risk for developing breast cancer, predominantly estrogen receptor positive tumors, to express specific polymorphic forms of endothelial nitric oxide synthase, that produce sustained low levels of nitric oxide. Low sustained nitric oxide generates oxidative stress and inflammatory conditions at susceptible sites in the heterogeneous microenvironment of the breast, where it promotes cancer related events in specific cell types. Inflammatory conditions also stimulate inducible nitric oxide synthase expression, which dependent on the microenvironment, could promote or inhibit mammary tumors. In this review we re-examine the mechanisms by which nitric oxide promotes initiation and progression of breast cancer and address some of the controversies in the field.
Keywords: Breast cancer, oxidative stress, estrogen, angiogenesis, inflammation, nitric oxide, proliferation
Current Pharmaceutical Design
Title: NO to Breast: When, Why and Why Not?
Volume: 16 Issue: 4
Author(s): Shehla Pervin, Gautam Chaudhuri and Rajan Singh
Affiliation:
Keywords: Breast cancer, oxidative stress, estrogen, angiogenesis, inflammation, nitric oxide, proliferation
Abstract: Nitric oxide is a pleiotropic ancestral molecule, which elicits beneficial effect in many physiological settings but is also tenaciously expressed in numerous pathological conditions, particularly breast tumors. Nitric oxide is particularly harmful in adipogenic milieu of the breast, where it initiates and promotes tumorigenesis. Epidemiological studies have associated populations at a greater risk for developing breast cancer, predominantly estrogen receptor positive tumors, to express specific polymorphic forms of endothelial nitric oxide synthase, that produce sustained low levels of nitric oxide. Low sustained nitric oxide generates oxidative stress and inflammatory conditions at susceptible sites in the heterogeneous microenvironment of the breast, where it promotes cancer related events in specific cell types. Inflammatory conditions also stimulate inducible nitric oxide synthase expression, which dependent on the microenvironment, could promote or inhibit mammary tumors. In this review we re-examine the mechanisms by which nitric oxide promotes initiation and progression of breast cancer and address some of the controversies in the field.
Export Options
About this article
Cite this article as:
Pervin Shehla, Chaudhuri Gautam and Singh Rajan, NO to Breast: When, Why and Why Not?, Current Pharmaceutical Design 2010; 16 (4) . https://dx.doi.org/10.2174/138161210790232130
DOI https://dx.doi.org/10.2174/138161210790232130 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4
Current Drug Metabolism Editorial [Hot topic: Innate Immunity Molecules S100A8/A9 Involved in Stress Response and Cancer Biology (Guest Editors: Claus Kerkhoff and Saeid Ghavami)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Fusion of MLO and CC View Binary Patterns to Improve the Performance of Breast Cancer Diagnosis
Current Medical Imaging Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Editorial (Thematic Issue: Cancer Biomarkers from Bench to Bedside)
Current Cancer Drug Targets Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Cholesterol: A Prelate in Cell Nucleus and its Serendipity
Current Molecular Medicine Drug Combinations in Breast Cancer Therapy
Pharmaceutical Nanotechnology Immunomodulatory Effect of Probiotic Bacteria
Recent Patents on Inflammation & Allergy Drug Discovery Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Regulation of Mammalian UDP-Glucuronosyltransferases
Current Drug Metabolism DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Design and Development of Oxazol-5-Ones as Potential Partial PPAR-γ Agonist Against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry